Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Bayer: Kmart bankruptcy, coupled with slow cough/cold season, 70% consumer sales dive in Argentina contribute to 9% drop in consumer care revenue to $449 mil. (€1 = $.8979) in the first quarter. Overall, Bayer health care sales dipped 5.5% to $2.16 bil., largely due to withdrawal of cholesterol-lowering drug Baycol last August (1"The Tan Sheet" Aug. 13, 2001, In Brief). Net income rose 18.3% to $469.6 mil. for the quarter, firm says...
You may also be interested in...
Herbalife Buyout By Equity Groups Achieves Long-Sought Private Ownership
The pending acquisition of Herbalife by equity firms Whitney & Co. and Golden Gate Capital ends a two-and-a-half year effort, initiated by late founder and CEO Mark Hughes, to take the direct marketer private
Statin adverse event?
Bayer withdraws Rx cholesterol-lowering statin Baycol (cerivastatin) due to prevalence of rhabdomyolysis, including 31 fatal cases, at low doses, FDA says Aug. 8. Agency suggests Baycol users talk to doctors about switching to alternative statins, including Merck's Mevacor and BMS' Pravachol, both of which were subject to OTC switch consideration last summer (1"The Tan Sheet" July 17, 2000, pp. 3-6). Public Citizen plans to petition FDA to include "black box" warning on all Rx statins informing patients of serious adverse event risks, group says
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC